Utilization of hypofractionated radiotherapy for breast cancer among Indonesian Radiation Oncologists during and after pandemic COVID-19
Sari
Background: The incidence of breast cancer (BC) increases over time. However, the availability of radiotherapy machines is minimal, especially after the COVID-19 pandemic. Hypofractionated radiotherapy (HFRT) may provide a solution for this situation. We intended to evaluate the practice of HFRT for BC patients amongst the Indonesian Radiation Oncologist Society members.
Material and methods: This study uses a Google Form questionnaire distributed personally in early October 2021. Statistical analysis uses descriptive and Chi-square/Fisher tests.
Results: Twenty-nine participants filled out the questionnaire. One-third of participants worked at Academic Hospital and were aged 35 - 45 years old. Most of the participants had working experience of fewer than ten years. 4 (13.8 %) and 3 (10.3 %) participants preferred HFRT for WBI with or without regional node irradiation. Only one participant selected HFRT for PMRT. 9 (31 %) and 8 (27.5 %) participants chose both HFRT and CFRT for postmastectomy with or without reconstruction.
Conclusion: The utilization of HFRT in routine practice amongst Indonesian RO is still low despite proven clinical benefits. Continuing medical education about evidence-based may increase the translation of clinical trials into daily practice.
Kata Kunci
Teks Lengkap:
PDF (English)Referensi
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941-1953. doi:10.1002/ijc.31937
Breast Cancer Trialists E, Group C. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Published online 2011. doi:10.1016/S0140
McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. The Lancet. 2014;383(9935):2127-2135. doi:10.1016/S0140-6736(14)60488-8
Kesehatan K, Penanggulangan K, Nasional K. KANKER PAYUDARA.
Coles CE, Aristei C, Bliss J, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology. 2020;32(5):279-281. doi:10.1016/j.clon.2020.03.006
J L, DQ H, B Z, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-1458. doi:10.1002/JMV.26424
Handoko, Permata TBM, Giselvania A, et al. Ensuring safety and sustainability of radiotherapy services during the COVID-19 pandemic in resources constrain country: An Indonesian experience. Radiotherapy and Oncology. 2020;150:57-60. doi:10.1016/j.radonc.2020.05.044
Spencer K, Jones CM, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. The Lancet Oncology. 2021;22(3):309-320. doi:10.1016/S1470-2045(20)30743-9
Group TST. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098. doi:10.1016/S0140-6736(08)60348-7
Group TST. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet Oncology. 2008;9(4):331. doi:10.1016/S1470-2045(08)70077-9
Brunt AM, Haviland J, Sydenham M, et al. FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology*Biology*Physics. 2018;102(5):1603-1604. doi:10.1016/J.IJROBP.2018.08.049
Gu L, Dai W, Fu R, et al. Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology. 2021;11. doi:10.3389/fonc.2021.753209
Liu L, Yang Y, Guo Q, et al. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiation Oncology 2020 15:1. 2020;15(1):1-15. doi:10.1186/S13014-020-1463-1
Yang J, Qi SN, Fang H, et al. Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer. Breast. 2021;58:72-79. doi:10.1016/j.breast.2021.04.002
Ratosa I, Chirilă ME, Steinacher M, et al. Hypofractionated radiation therapy for breast cancer: Preferences amongst radiation oncologists in Europe – Results from an international survey. Radiotherapy and Oncology. 2021;155:17-26. doi:10.1016/j.radonc.2020.10.008
DOI: https://doi.org/10.32532/jori.v15i1.150 <
Article metrics
Abstract views : 32
| 
views : 27
Refbacks
- Saat ini tidak ada refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.